| Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor … J Kmiecik, A Poli, NHC Brons, A Waha, GE Eide, PØ Enger, J Zimmer, ... Journal of neuroimmunology 264 (1-2), 71-83, 2013 | 405 | 2013 |
| Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics C Krakstad, M Chekenya Molecular cancer 9, 1-14, 2010 | 385 | 2010 |
| Angiogenesis-independent tumor growth mediated by stem-like cancer cells PØ Sakariassen, L Prestegarden, J Wang, KO Skaftnesmo, ... Proceedings of the National Academy of Sciences 103 (44), 16466-16471, 2006 | 262 | 2006 |
| Therapeutic potential and challenges of natural killer cells in treatment of solid tumors A Gras Navarro, AT Björklund, M Chekenya Frontiers in immunology 6, 139254, 2015 | 214 | 2015 |
| Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies PØ Sakariassen, H Immervoll, M Chekenya Neoplasia 9 (11), 882-892, 2007 | 195 | 2007 |
| The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling M Chekenya, C Krakstad, A Svendsen, IA Netland, V Staalesen, ... Oncogene 27 (39), 5182-5194, 2008 | 187 | 2008 |
| U‐251 revisited: genetic drift and phenotypic consequences of long‐term cultures of glioblastoma cells A Torsvik, D Stieber, PØ Enger, A Golebiewska, A Molven, A Svendsen, ... Cancer medicine 3 (4), 812-824, 2014 | 183 | 2014 |
| Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma A Svendsen, JJC Verhoeff, H Immervoll, JC Brøgger, J Kmiecik, A Poli, ... Acta neuropathologica 122, 495-510, 2011 | 152 | 2011 |
| NG2 proteoglycan promotes angiogenesis‐dependent tumor growth in the central nervous system by sequestering angiostatin M Chekenya, M Hjelstuen, PØ Enger, F Thorsen, AL Jacob, B Probst, ... The FASEB Journal 16 (6), 586-588, 2002 | 150 | 2002 |
| Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma J Wang, A Svendsen, J Kmiecik, H Immervoll, KO Skaftnesmo, ... PloS one 6 (7), e23062, 2011 | 140 | 2011 |
| The NG2 chondoitin sulfate proteoglycan: role in malignant progression of human brain tumours M Chekenya, HK Rooprai, D Davies, JM Levine, AM Butt, GJ Pilkington International journal of developmental neuroscience 17 (5-6), 421-435, 1999 | 133 | 1999 |
| A reproducible brain tumour model established from human glioblastoma biopsies J Wang, H Miletic, PØ Sakariassen, PC Huszthy, H Jacobsen, N Brekkå, ... BMC cancer 9, 1-13, 2009 | 120 | 2009 |
| The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours M Chekenya, PØ Enger, F Thorsen, BB Tysnes, S Al‐Sarraj, TA Read, ... Neuropathology and applied neurobiology 28 (5), 367-380, 2002 | 119 | 2002 |
| Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival A Poli, J Wang, O Domingues, J Planagumà, T Yan, CB Rygh, ... Oncotarget 4 (9), 1527, 2013 | 112 | 2013 |
| NG2 precursor cells in neoplasia: functional, histogenesis and therapeutic implications for malignant brain tumours M Chekenya, GJ Pilkington Journal of neurocytology 31 (6), 507 ppl=-521, 2002 | 112 | 2002 |
| NK cells in central nervous system disorders A Poli, J Kmiecik, O Domingues, F Hentges, M Bléry, M Chekenya, ... The Journal of Immunology 190 (11), 5355-5362, 2013 | 110 | 2013 |
| Hyperoxic treatment induces mesenchymal-to-epithelial transition in a rat adenocarcinoma model I Moen, AM Øyan, KH Kalland, KJ Tronstad, LA Akslen, M Chekenya, ... PloS one 4 (7), e6381, 2009 | 97 | 2009 |
| Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours J Kmiecik, J Zimmer, M Chekenya Journal of Neuro-oncology 116, 1-9, 2014 | 80 | 2014 |
| NG2 expression regulates vascular morphology and function in human brain tumours C Brekke, A Lundervold, PØ Enger, C Brekken, E Stålsett, TB Pedersen, ... Neuroimage 29 (3), 965-976, 2006 | 71 | 2006 |
| NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival A Gras Navarro, J Kmiecik, L Leiss, M Zelkowski, A Engelsen, Ø Bruserud, ... The Journal of Immunology 193 (12), 6192-6206, 2014 | 63 | 2014 |
